This Story Is Heating Back Up…  (OTC:BSEM) 

we have seen Biostem hit these leves before and we have also seen it bounce pretty hard from here… With stellar financials and 2026 right around the corner can we see one more push into the the new year?? 

Here we go humans!! 

OTC:BSEM IS here!!! 

BioStem Technologies (BSEM): Q3 2025 Earnings Highlight Strong Financial Resilience, Consecutive Profitable Quarters, and there’s Nasdaq Uplisting Potential with a $25.50 Zacks Price Target!

BSEM posts positive adjusted EBITDA for the seventh straight quarter, drives product adoption with clinically validated BioREtain® allografts, and expands access across high-value healthcare channels.

Hello Everyone,

The MedTech sector—where cutting-edge technology meets modern medicine—is among the fastest-growing and most resilient industries today. As global healthcare spending rises and populations continue to age, the demand for advanced medical solutions is surging. 

Even in economic slowdowns, healthcare spending tends to remain robust, and many MedTech companies operate in mission-critical markets that are still underpenetrated. 

This is exactly where BioStem Technologies (OTC: BSEM) distinguishes itself!

Who is BSEM?

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care.

The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure.

BSEM’s quality management systems are accredited by the American Association of Tissue Banks (“AATB”) and adhere to current Good Tissue Practices (cGTP). Its portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC™. Each BioStem Technologies placental allograft is processed at the Company’s FDA registeredand AATB accredited site in Pompano Beach, Florida.

Quarterly Earnings Snapshot: Resilience Amid Challenges

BSEM delivered a solid Q3 2025 performance, reporting $10.5 million in net revenue and $0.8 million in GAAP net income. 

While revenue slightly declined from $11 million in Q2, the company achieved its seventh consecutive quarter of positive adjusted EBITDA at $2.7 million!

This underscored operational discipline and financial resilience. Gross margin decreased to 88.5% due to a shift toward licensing-based products, and cash balances totaled $27.2 million following land acquisitions and timing of collections. 

CEO Jason Matuszewski emphasized that the company remains well-positioned to navigate evolving reimbursement models while pursuing strategic growth initiatives.

“This quarter underscored the resilience of our business model, the discipline of our operations, and the strength of our team as we continued to execute through an evolving reimbursement landscape. BioStem remains well positioned financially, operationally, and clinically to lead through this transition and emerge even stronger,” said Matuszewski.

Validated Technology Driving Adoption

BioStem’s BioREtain® allografts continue to set the standard in regenerative wound care. 

Recent Level 1 randomized controlled trial results for diabetic foot ulcers demonstrated superior outcomes versus standard of care. 

A pivotal moment for BSEM came with the publication of its groundbreaking clinical trial in the International Journal of Tissue Repair. The peer-reviewed study evaluated the company’s proprietary BioRetain® amnion chorion allograft in patients suffering from non-healing diabetic foot ulcers (DFUs) — one of the most challenging and costly chronic conditions in modern medicine.

The results were extraordinary:

• 53% probability of complete wound closure using BioRetain®, versus just 31% for standard of care.
• Conducted under FDA-level clinical rigor, the study focused on real-world, hard-to-heal ulcers.
• Findings demonstrate superior durability, faster healing, and sustained closure — critical metrics for long-term patient outcomes.

Dr. Bert Slade, Chairman of BioStem’s Medical Advisory Board, called the results “strong evidence of treatment benefit,” reinforcing BioStem’s leadership in regenerative tissue technology. 

These findings not only validate the company’s proprietary BioRetain® process but also highlight its potential to transform the $27 billion global wound care market.

The venous leg ulcer trial is progressing ahead of schedule, with top-line results expected in Q1 2026. This is just around the corner…

“We are very pleased that this study has demonstrated the effectiveness of BioRetain-processed placental allografts in achieving wound closure in patients with hard-to-heal wounds,” said Jason Matuszewski. “Previously reported comparisons of BioRetain versus competitive technologies have demonstrated its superiority in retaining the natural structural and molecular composition of the native tissue. This study reinforces the clinical performance of our technology.”

Diabetic Foot Ulcers

Diabetic foot ulcers are a serious and chronic condition affecting millions of individuals within the diabetic population. 

According to the American Podiatric Medical Association (APMA), a leading authority on foot and ankle health, approximately 15% of people with diabetes will develop foot ulcers. 

Alarmingly, 6% of these individuals may require hospitalization due to infections or other complications related to their ulcers. The risks for diabetic patients are substantial, as DFUs are the leading cause of lower extremity amputations in the U.S. Studies indicate that between 14% and 24% of individuals with diabetes who develop foot ulcers will ultimately need an amputation.

The economic burden of these ulcers on healthcare systems is significant, with annual treatment costs estimated between $9 billion and $13 billion in the U.S. alone. As the population continues to age, this financial strain is expected to intensify, underscoring the need for more effective and accessible treatment options such as what BSEM offers.

BioStem expects product margins to remain robust under the new CMS reimbursement model. “We believe BioStem is exceptionally well-positioned to thrive in this environment,” added Matuszewski. 

“Our combination of clinically validated products, advanced GMP-compliant manufacturing, and efficient cost structure enables us to compete effectively even as the industry transitions to standardized reimbursement. We anticipate that CMS’s reforms will accelerate provider adoption of technology like BioREtain that delivers proven outcomes and economic value.”

Market Expansion: New Channels Unlock Growth Potential

BSEM is expanding its commercial reach through strategic partnerships, including a Service-Disabled Veteran-Owned Small Business to serve the Department of Veteran Affairs and early traction in state Medicaid programs such as Texas. 

The American Amnion launch at the Desert Foot Conference highlights entry into new federal and state markets, with broader access across additional programs planned in 2026. Combined with hospital and ASC initiatives, these moves target a total addressable market estimated at $300–$350 million!

Looking Ahead: Nasdaq Uplisting and Institutional Access

BSEM is actively pursuing a Nasdaq uplisting, targeting mid-2026 following completion of KPMG audits and SEC engagement. This milestone is expected to boost liquidity, attract institutional investors, and increase visibility among MedTech peers. 

Combined with a growing patent portfolio, FDA-registered and AATB-accredited facilities, and national reimbursement coverage,BSEM is positioned to capture significant market share in regenerative medicine.

The Bottom Line

With a $25.50 Zacks Small Cap Research price target, BSEMstands out as a high-growth MedTech investment. 

The company’s combination of profitable operations, clinically validated products, operational efficiency, and expanding market access positions BSEM for continued success.

While reimbursement changes and pricing pressures present short-term challenges, BSEM’s strong fundamentals, strategic expansion, and Nasdaq uplisting potential make it an attractive opportunity for investors seeking exposure to regenerative medicine. 

Start your own research!

Disclaimer 

We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Huge Alerts nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Huge Alerts. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Huge Alerts makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
Some of the content on this website contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results.
Generally, the information regarding a company profiled or discussed on this website is provided from public sources hugealerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Huge Alerts has no obligation to update any of the information provided. Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Huge Alerts encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Huge Alerts control, endorse, or guarantee any content found in such sites. Huge Alerts does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Huge Alerts, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Huge Alerts, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Huge Alerts uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.


Income Disclaimer

Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.

Huge Alerts has been retained by Biostem Technologies (OTC:BSEM) to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from Biostem Technologies (OTC:BSEM). Questions regarding this website may be sent to editor@hugealerts.com

Huge Alerts has an ongoing agreement with Biostem Technologies (OTC:BSEM) for the total sum of $2,900,500.00 This agreement is for the marketing of Biostem Technologies (OTC:BSEM) which services include the issuance of this release and other opinions that we release concerning of Biostem Technologies (OTC:BSEM). The Owner(s) of huge alerts own 4,365  free trading  shares of  Biostem Technologies (OTCS:BSEM) and 63,333 restricted shares. for the purpose of this disclaimer assume that the owners of huge alerts will sell every share at any time. Huge Alerts has not investigated the background of Biostem Technologies (OTC:BSEM) the hiring party, or Biostem Technologies (OTC:BSEM) Anyone viewing this newsletter should assume Biostem Technologies (OTC:BSEM) or affiliates of Biostem Technologies (OTC:BSEM) own shares of the Biostem Technologies (OTC:BSEM)) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Huge Alerts has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Biostem Technologies (OTC:BSEM)
 

1389 Center Dr
Park City UT 84098
USA

Unsubscribe   |   Change Subscriber Options